Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on October 1, 2019. The registrant is a Delaware corporation with principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance data.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement of a clinical trial data presentation.
Outlook, Risks, and Management Commentary
On October 1, 2019, Trovagene, Inc. announced the presentation of data from its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI and Avastin (bevacizumab). The study focuses on patients with KRAS-mutated metastatic Colorectal Cancer (mCRC). The data was presented in a poster format at the European Society for Medical Oncology (ESMO) Annual Congress. A copy of the press release is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical trial results and safety data.
- Confirm the company name is Trovagene, Inc., as the input metadata incorrectly referenced Cardiff Oncology, Inc.
- Review the ESMO Annual Congress proceedings for the detailed poster presentation content.
- Check subsequent filings for any regulatory updates or changes in the development timeline for onvansertib.